Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
IMMU's Cash to Debt is ranked higher than
81% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 20.79 vs. IMMU: No Debt )
IMMU' s 10-Year Cash to Debt Range
Min: 0.41   Max: No Debt
Current: No Debt

Equity to Asset 0.84
IMMU's Equity to Asset is ranked higher than
86% of the 766 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. IMMU: 0.84 )
IMMU' s 10-Year Equity to Asset Range
Min: -0.3   Max: 0.92
Current: 0.84

-0.3
0.92
Interest Coverage No Debt
IMMU's Interest Coverage is ranked higher than
98% of the 429 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. IMMU: No Debt )
IMMU' s 10-Year Interest Coverage Range
Min: 354.57   Max: 9999.99
Current: No Debt

354.57
9999.99
F-Score: 5
Z-Score: 15.26
M-Score: -2.51
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -389.97
IMMU's Operating margin (%) is ranked higher than
60% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -65.07 vs. IMMU: -389.97 )
IMMU' s 10-Year Operating margin (%) Range
Min: -782.35   Max: 55.69
Current: -389.97

-782.35
55.69
Net-margin (%) -388.28
IMMU's Net-margin (%) is ranked higher than
60% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -70.66 vs. IMMU: -388.28 )
IMMU' s 10-Year Net-margin (%) Range
Min: -782.35   Max: 60.72
Current: -388.28

-782.35
60.72
ROE (%) -106.44
IMMU's ROE (%) is ranked higher than
58% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -21.70 vs. IMMU: -106.44 )
IMMU' s 10-Year ROE (%) Range
Min: -1147.9   Max: 740.72
Current: -106.44

-1147.9
740.72
ROA (%) -90.00
IMMU's ROA (%) is ranked higher than
56% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: -18.92 vs. IMMU: -90.00 )
IMMU' s 10-Year ROA (%) Range
Min: -74.76   Max: 74.44
Current: -90

-74.76
74.44
ROC (Joel Greenblatt) (%) -1724.06
IMMU's ROC (Joel Greenblatt) (%) is ranked higher than
60% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -215.73 vs. IMMU: -1724.06 )
IMMU' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1787.04   Max: 721.44
Current: -1724.06

-1787.04
721.44
Revenue Growth (%) -18.10
IMMU's Revenue Growth (%) is ranked higher than
66% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. IMMU: -18.10 )
IMMU' s 10-Year Revenue Growth (%) Range
Min: -57.8   Max: 83.3
Current: -18.1

-57.8
83.3
EBITDA Growth (%) 21.30
IMMU's EBITDA Growth (%) is ranked higher than
96% of the 626 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. IMMU: 21.30 )
IMMU' s 10-Year EBITDA Growth (%) Range
Min: -25.5   Max: 54.2
Current: 21.3

-25.5
54.2
EPS Growth (%) 28.10
IMMU's EPS Growth (%) is ranked higher than
93% of the 645 Companies
in the Global Biotechnology industry.

( Industry Median: -10.20 vs. IMMU: 28.10 )
IMMU' s 10-Year EPS Growth (%) Range
Min: -36.3   Max: 84.2
Current: 28.1

-36.3
84.2
» IMMU's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

IMMU Guru Trades in

Q3 2013

IMMU Guru Trades in Q3 2013

Jim Simons 260,207 sh (New)
Steven Cohen 1,810,000 sh (New)
» More
Q4 2013

IMMU Guru Trades in Q4 2013

Paul Tudor Jones 18,678 sh (New)
Jim Simons Sold Out
Steven Cohen 1,398,548 sh (-22.73%)
» More
Q1 2014

IMMU Guru Trades in Q1 2014

Steven Cohen Sold Out
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with IMMU

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 6.81
IMMU's P/B is ranked higher than
71% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 6.41 vs. IMMU: 6.81 )
IMMU' s 10-Year P/B Range
Min: 4.32   Max: 249
Current: 6.81

4.32
249
P/S 32.00
IMMU's P/S is ranked higher than
69% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 20.67 vs. IMMU: 32.00 )
IMMU' s 10-Year P/S Range
Min: 2.97   Max: 103
Current: 32

2.97
103
EV-to-EBIT -7.80
IMMU's EV-to-EBIT is ranked higher than
66% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. IMMU: -7.80 )
IMMU' s 10-Year EV-to-EBIT Range
Min: 5.8   Max: 175.3
Current: -7.8

5.8
175.3
Current Ratio 6.90
IMMU's Current Ratio is ranked lower than
82% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 4.31 vs. IMMU: 6.90 )
IMMU' s 10-Year Current Ratio Range
Min: 0.6   Max: 11.92
Current: 6.9

0.6
11.92
Quick Ratio 6.78
IMMU's Quick Ratio is ranked lower than
82% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 3.96 vs. IMMU: 6.78 )
IMMU' s 10-Year Quick Ratio Range
Min: 0.59   Max: 11.63
Current: 6.78

0.59
11.63

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.80
IMMU's Price/Net Cash is ranked higher than
89% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 190.00 vs. IMMU: 7.80 )
IMMU' s 10-Year Price/Net Cash Range
Min: 8.4   Max: 218.75
Current: 7.8

8.4
218.75
Price/Net Current Asset Value 7.62
IMMU's Price/Net Current Asset Value is ranked higher than
88% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 79.32 vs. IMMU: 7.62 )
IMMU' s 10-Year Price/Net Current Asset Value Range
Min: 8.02   Max: 145.83
Current: 7.62

8.02
145.83
Price/Tangible Book 6.81
IMMU's Price/Tangible Book is ranked higher than
77% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9.62 vs. IMMU: 6.81 )
IMMU' s 10-Year Price/Tangible Book Range
Min: 3.08   Max: 84.67
Current: 6.81

3.08
84.67
Price/Median PS Value 1.19
IMMU's Price/Median PS Value is ranked higher than
81% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. IMMU: 1.19 )
IMMU' s 10-Year Price/Median PS Value Range
Min: 0.14   Max: 7.59
Current: 1.19

0.14
7.59
Earnings Yield (Greenblatt) 0.50
IMMU's Earnings Yield (Greenblatt) is ranked higher than
51% of the 469 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. IMMU: 0.50 )
IMMU' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.6   Max: 17.4
Current: 0.5

0.6
17.4

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:IM3.Germany
Immunomedics, Inc., was incorporated in Delaware in 1982. It is a biopharmaceutical company which develops monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. It has developed advanced proprietary technologies that allow it to create humanized antibodies that can be used either alone in unlabeled or 'naked' form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins, in each case to create targeted agents. Using these technologies, it has built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. Its product candidate, epratuzumab, is currently in two Phase III clinical trials in lupus. In oncology, the Company is planning to launch a Phase III pivotal trial for clivatuzumab labeled with a radioisotope in pancreatic cancer patients. Other solid tumor therapeutics in Phase II clinical development includes 2 antibody-drug conjugates; labetuzumab-SN-38 (IMMU-130) and hRS7-SN-38 (IMMU-132).It also have a majority ownership in IBC Pharmaceuticals, Inc., which is developing a DOCK-AND-LOCK (DNL) method with for making fusion proteins and multifunctional antibodies. DNL is being used particularly to make bispecific antibodies targeting cancers and infectious diseases as a T-cell redirecting immunotherapy, as well as bispecific antibodies for next-generation cancer and autoimmune disease therapies. It has licensed its product candidate, epratuzumab, to UCB S.A., or UCB, for the treatment of all non-cancer indications worldwide. Epratuzumab's advanced clinical testing is for the treatment of systemic lupus erythematosus, or SLE (lupus), in non-Hodgkin lymphoma, or NHL and acute lymphoblastic leukemia, or ALL. During the 2013 fiscal year, it have completed a Phase Ib clinical trial evaluating clivatuzumab tetraxetan (hPAM4) labeled with yttrium-90, or Y-90, with and without low-dose gemcitabine, in pancreatic cancer patients who had received at least 2 prior therapies. It also initiated a randomized Phase Ib study examining the Y-90-labeled clivatuzumab tetraxetan, with and without low-dose gemcitabine, in pancreatic cancer patients who have received at least 2 prior therapies. It is also conducting a National Cancer Institute, or NCI, grant-supported study combining unlabeled veltuzumab with Y-90-labeled epratuzumab tetraxetan in patients with diffuse large B-cell lymphoma, or DLBCL, the aggressive form of NHL. The second ADC in its product pipeline is, labetuzumab-SN-38, which is in a Phase I/II trial in patients with advanced colorectal cancer. In the first half of fiscal 2013, it plan to begin a new study examining the safety and tolerability of its third ADC, hRS7-SN-38, in patients with solid cancers, for which an Investigational New Drug (IND) application has been filed with the Food and Drug Administration (FDA). The Company competes with Biogen Idec, Roche, GlaxoSmithKline, Seattle Genetics, Merck Sero
» More Articles for IMMU

Headlines

Articles On GuruFocus.com
Immunomedics Inc. Reports Operating Results (10-Q) Feb 04 2011 
Immunomedics Inc. Reports Operating Results (10-Q) Nov 04 2010 
Immunomedics Inc. Reports Operating Results (10-K) Aug 26 2010 
Fastest Growing Magic Formula Stocks: Jiangbo Pharmaceuticals, DragonWave, Immunomedics, Genoptix, P Jul 15 2010 
Immunomedics Inc. Reports Operating Results (10-Q) May 10 2010 
Immunomedics Inc. Reports Operating Results (10-Q) Feb 02 2010 
Immunomedics Inc. Reports Operating Results (10-Q) Nov 06 2009 
Immunomedics Inc. Reports Operating Results (10-K) Aug 27 2009 
Immunomedics Inc. Reports Operating Results (10-Q) May 11 2009 
Immunomedics Inc. Reports Operating Results (10-Q) Feb 09 2009 

More From Other Websites
IMMUNOMEDICS INC Financials Aug 30 2014
Immunomedics' Posts in Line Q4 Loss, Revenues Decline Y/Y Aug 28 2014
Immunomedics downgraded by R. F. Lafferty Aug 27 2014
IMMUNOMEDICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 25 2014
Immunomedics Announces Fiscal 2014 Results and Clinical Program Developments Aug 25 2014
IMMUNOMEDICS INC Files SEC form 8-K, Change in Directors or Principal Officers Aug 20 2014
Immunomedics Announces Conference Call and Webcast for Fourth Quarter and Fiscal Year 2014 Financial... Aug 11 2014
IMMUNOMEDICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Jun 25 2014
Immunomedics' IMMU-132 Gets Orphan Drug Status Jun 10 2014
Immunomedics announces IMMU-132 orphan drug designation Jun 09 2014
Immunomedics announces presentation of epratuzumab data Jun 09 2014
Immunomedics reports positive results from study of IMMU-132 Jun 02 2014
CollabRx's Mobile App Simplifies Cancer Treatment Options May 29 2014
IMMUNOMEDICS INC Files SEC form 8-K, Other Events May 23 2014
Immunomedics says IMMU-132 'well tolerated' in Phase I/II study May 20 2014
Immunomedics announces U.S. patent for IMMU-144 May 13 2014
Immunomedics' (IMMU) CEO Cynthia Sullivan on F3Q 2014 Results - Earnings Call Transcript May 11 2014
IMMUNOMEDICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 07 2014
IMMUNOMEDICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... May 02 2014
Immunomedics seen holding firm May 02 2014
Immunomedics files to sell common stock, no amount given May 01 2014
ALERT: Rosen Law Firm Reminds Immunomedics, Inc. Investors of Important April 28, 2014 Class Action... Apr 22 2014
IMMUNOMEDICS EXTENDS PATENT LIFE ON THERAPEUTIC ANTIBODIES Feb 26 2014
IMMUNOMEDICS TO PRESENT AT COWEN AND COMPANY 34TH ANNUAL HEALTH CARE CONFERENCE Feb 26 2014
IMMUNOMEDICS ANNOUNCES SECOND QUARTER FISCAL 2014 RESULTS AND CLINICAL PROGRAM DEVELOPMENTS Feb 10 2014
IMMUNOMEDICS RANKS 4TH IN THE PATENT BOARD BIOTECHNOLOGY INDUSTRY SCORECARD Feb 04 2014
IMMUNOMEDICS ANNOUNCES U.S. PATENT FOR ANTIBODY-SN-38 CONJUGATES Dec 31 2013
IMMUNOMEDICS REPORTS PROMISING ACTIVITY WITH VELTUZUMAB IN RELAPSED IMMUNE THROMBOCYTOPENIA Dec 09 2013
IMMUNOMEDICS ANNOUNCES ORPHAN DRUG DESIGNATION FOR IMMU-132 FOR SMALL CELL LUNG CANCER THERAPY Dec 04 2013
IMMUNOMEDICS ANNOUNCES OUTCOME OF 2013 ANNUAL MEETING OF STOCKHOLDERS Dec 04 2013
IMMUNOMEDICS TO PRESENT AT OPPENHEIMER 24TH ANNUAL HEALTHCARE CONFERENCE Dec 03 2013
IMMUNOMEDICS ANNOUNCES IMMU-132 IS ACTIVE IN PATIENTS REFRACTORY TO IRINOTECAN Nov 08 2013
IMMUNOMEDICS AWARDED KEY PATENT FOR TROP-2 ANTIBODY Nov 05 2013
IMMUNOMEDICS ANNOUNCES FIRST QUARTER FISCAL 2014 RESULTS AND CLINICAL PROGRAM DEVELOPMENTS Nov 04 2013

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK